HTBX: Picture of a Pump & Dump

Heat Biologics, Inc. Prices $18,000,000 Public Offering

DURHAM, NC / ACCESSWIRE / May 3, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the pricing of an underwritten public offering with gross proceeds of approximately $18,000,000, before deducting underwriting discounts, commissions and other offering expenses. The offering consists of: (i) 3,000,000 shares of our Common Stock together with a number of Common Warrants to purchase 1,500,000 shares of our Common Stock, and (ii) 9,500,000 Pre-funded Warrants, with each Pre-funded Warrant exercisable for one share of Common Stock, together with a number of Common Warrants to purchase 4,750,000 shares of our Common Stock.
The Common Warrants will have an exercise price of $1.584, will be exercisable upon issuance and will expire five years from the date of issuance. Heat Biologics, Inc. has granted the underwriters a 45-day option to purchase up to an additional 1,875,000 shares of Common Stock and/or 937,500 Common Warrants to cover over-allotments if any. The offering is expected to close on May 7, 2018, subject to customary closing conditions.

A.G.P./Alliance Global Partners, offering securities through Euro Pacific Capital, Inc., is acting as the sole book-running manager for the offering.
CIM Securities, LLC is acting as a Co-Manager for the offering.

A registration statement on Form S-1 (No. 333-224039) relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") and became effective on May 2, 2018 and is available on the SEC's website located at www.sec.gov. This offering is being made only by means of a prospectus. Electronic copies of the prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, offering securities through Euro Pacific Capital, Inc., 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2006 or email: prospectus@allianceg.com. Before investing in this offering, interested parties should read in their entirety the prospectus and the other documents that Heat Biologics, Inc. has filed with the SEC that are incorporated by reference in such prospectus, which provides more information about Heat Biologics, Inc. and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Heat Biologics
Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer by inducing CD8+ "Killer" T-cells. Heat's T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitor therapies and other immuno-modulators to increase their effectiveness. Heat is currently enrolling patients in its Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. Heat also has numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Sure thing, Doe.

It's illegal. Allowed to happen due to lack of policing and enforcement.

Might be another one in progress.......VVPR. Up from a buck to 6 in two days and no news. 300K volume ydy, 10M volume today, so far.

Take a closer look at the daily chart for the last year. Then look at what it did since the Apr 2 gap down in relation to what it did since early Oct 2017. Also look at the vol since Apr 2. Your perspective might be different.

Well, now there is at least some PR-based justification for a move up, whereas there was none for the move all the way up to 4.30 on yuuuuge volume.

It was a pump and dump if there ever was one. And the timing was exquisite. Two days after reaching the peak, they announce a stock offering priced at 1.54, and price gaps right back down to where it was before the  P&D trapping the hapless mo-mo chasers with a $3/sh loss.  Volume on the 2nd day of the run up was 22M ranging from 3.20 to 4.30.  6.2M got out the next day ranging 2.36 to 3.37. And on the monster gap down to 1.22 to 1.32 only 8.6M shares were traded.

In round numbers, roughly 8M shares were stuck with a big loss.

That RS is showing up in TOS this time.